Literature DB >> 12704688

Stability of archived liquid-based cervical cytologic specimens.

Philip E Castle1, Diane Solomon, Allan Hildesheim, Rolando Herrero, M Concepcion Bratti, Mark E Sherman, Ana Cecilia Rodriguez, Mario Alfaro, Martha L Hutchinson, S Terence Dunn, Jane Kuypers, Mark Schiffman.   

Abstract

BACKGROUND: Exfoliated cervical cell specimens collected in PreservCyt, a methanol-based medium used in ThinPrep liquid-based cytology, have been archived in epidemiologic studies. However, long-term DNA stability and cytologic stability of these biospecimens have not been evaluated.
METHODS: Cervical specimens were collected into PreservCyt from participants in a natural history study of human papillomavirus (HPV) infection and cervical carcinoma in Guanacaste, Costa Rica (1993-2000), and stored at ambient temperatures. Thirty specimens classified as low-grade squamous intraepithelial lesions by liquid-based cytology were randomly chosen from each collection year (except for 1994) and selectively assessed for molecular and cytologic stability. Specimens were tested in 2001 for 1) HPV DNA by the Hybrid Capture 2 test, 2) beta-globin DNA by polymerase chain reaction amplification of multiple length fragments (268, 610, and 1327 bp), and 3) nuclear preservation by visual inspection of newly made liquid-based cytology slides. All testing was done masked to year of collection. Associations of stability and storage time were evaluated using standard contingency tables and chi-square tests for trend.
RESULTS: Human papillomavirus DNA, as detected by the Hybrid Capture 2 test, was unaffected by storage time. Stability of beta-globin DNA (P(Trend) < 0.0001) and nuclear preservation (P(Trend) < 0.0001) declined with increasing storage time. Approximately 15% of specimens could not be amplified for any beta-globin DNA fragment after 5 years of storage (collected in 1996). In addition, cytology slides made from 41% specimens were rated as marginal (32%) or unsatisfactory (9%) after 8 years of storage (collected in 1993).
CONCLUSIONS: Cervical specimens archived in PreservCyt underwent partial DNA and cytologic degradation after several years of storage. Methodologic studies to optimize long-term storage of cervical cells for epidemiologic studies of cervical carcinoma are needed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704688     DOI: 10.1002/cncr.11058

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Detection of nuclear and membrane antigens by liquid-based cytology following long-term storage of d1 cells, karpas cells, and peripheral blood mononuclear cells.

Authors:  Roberta Zappacosta; Francesca B Aiello; Tommaso D'Antuono; Antonio D Procopio; Scott K Durum; Pio Conti; Sandra Rosini
Journal:  Ann Clin Lab Sci       Date:  2011       Impact factor: 1.256

2.  A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.

Authors:  Cosette M Wheeler; William C Hunt; Jack Cuzick; Erika Langsfeld; Amanda Pearse; George D Montoya; Michael Robertson; Catherine A Shearman; Philip E Castle
Journal:  Int J Cancer       Date:  2012-06-20       Impact factor: 7.396

Review 3.  Human papillomavirus infections in primary care.

Authors:  Folashade Ogunmodede; Steven H Yale; Bruce Krawisz; Gregory C Tyler; Anthony C Evans
Journal:  Clin Med Res       Date:  2007-12-17

4.  Long-term stability of human genomic and human papillomavirus DNA stored in BD SurePath and Hologic PreservCyt liquid-based cytology media.

Authors:  Patricia M Agreda; Gerard H Beitman; Erin C Gutierrez; James M Harris; Kristopher R Koch; William D LaViers; Sharon V Leitch; Courtney E Maus; Ray A McMillian; William A Nussbaumer; Marcus L R Palmer; Michael J Porter; Gregory A Richart; Ryan J Schwab; Laurence M Vaughan
Journal:  J Clin Microbiol       Date:  2013-05-15       Impact factor: 5.948

5.  Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.

Authors:  Francesca Carozzi; Simonetta Bisanzi; Cristina Sani; Marco Zappa; Silvia Cecchini; Stefano Ciatto; Massimo Confortini
Journal:  J Clin Microbiol       Date:  2006-11-22       Impact factor: 5.948

Review 6.  Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia.

Authors:  Kate Cuschieri; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-10       Impact factor: 4.254

7.  Next-generation sequencing of residual cytologic fixative preserved DNA from pancreatic lesions: A pilot study.

Authors:  Clifton G Fulmer; Kyung Park; Thomas Dilcher; Mai Ho; Susanna Mirabelli; Susan Alperstein; Erika M Hissong; Meredith Pittman; Momin Siddiqui; Jonas J Heymann; Rhonda K Yantiss; Alain C Borczuk; Helen Fernandes; Carlie Sigel; Wei Song; Juan Miguel Mosquera; Rema Rao
Journal:  Cancer Cytopathol       Date:  2020-06-29       Impact factor: 4.264

8.  Cervical Cytology Specimen Stability in Surepath Preservative and Analytical Sensitivity for HPV Testing with the cobas and Hybrid Capture 2 Tests.

Authors:  Keith D Tardif; Michael T Pyne; Elisabeth Malmberg; Tatum C Lunt; Robert Schlaberg
Journal:  PLoS One       Date:  2016-02-23       Impact factor: 3.240

9.  Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework.

Authors:  K Cuschieri; D T Geraets; C Moore; W Quint; E Duvall; M Arbyn
Journal:  J Clin Microbiol       Date:  2015-08-05       Impact factor: 5.948

10.  Comparing the Performance of Hybrid Capture II and Polymerase Chain Reaction (PCR) for the Identification of Cervical Dysplasia in the Screening and Diagnostic Settings.

Authors:  Hung N Luu; Karen Adler-Storthz; Laura M Dillon; Michele Follen; Michael E Scheurer
Journal:  Clin Med Insights Oncol       Date:  2013-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.